Key Factors Influencing Treatment Selection in Relapsed and Refractory Multiple Myeloma - onclive.com
Key Factors Influencing Treatment Selection in Relapsed and Refractory Multiple Myeloma onclive.com
Multiple Myeloma News
Teclistamab Plus Daratumumab Approval Marks Milestone in Myeloma Care: Ajai Chari, MD - The American Journal of Managed Care® (AJMC®)
Teclistamab Plus Daratumumab Approval Marks Milestone in Myeloma Care: Ajai Chari, MD The American Journal of Managed Care® (AJMC®)
Myelo 2026: Virtual Global Congress on Multiple Myeloma - Oncodaily
Myelo 2026: Virtual Global Congress on Multiple Myeloma Oncodaily
Teclistamab Combo Approval is ‘Excellent’ for R/R Multiple Myeloma - CancerNetwork
Teclistamab Combo Approval is ‘Excellent’ for R/R Multiple Myeloma CancerNetwork
Collaborative Care Is Redefining Survival in Multiple Myeloma - Pharmacy Times
Collaborative Care Is Redefining Survival in Multiple Myeloma Pharmacy Times
Treatment Sequencing Strategies in Relapsed and Refractory Multiple Myeloma - onclive.com
Treatment Sequencing Strategies in Relapsed and Refractory Multiple Myeloma onclive.com
Rapid Novor Announces Completion of Patient Enrollment in Princess Margaret Cancer Centre Study Evaluating EasyM® in Multiple Myeloma - PRWeb
Rapid Novor Announces Completion of Patient Enrollment in Princess Margaret Cancer Centre Study Evaluating EasyM® in Multiple Myeloma PRWeb
Enhanced dynamic risk stratification of smoldering multiple myeloma - Nature
Enhanced dynamic risk stratification of smoldering multiple myeloma Nature
1st patient dosed in trial of all-oral myeloma treatment combo - Rare Cancer News
1st patient dosed in trial of all-oral myeloma treatment combo Rare Cancer News
Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030 - Seeking Alpha
Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030 Seeking Alpha
New advances are transforming blood cancer care - Loma Linda University
New advances are transforming blood cancer care Loma Linda University
New Standard of Multiple Myeloma Care? FDA Approves Tecvayli Combination - Cure Today
New Standard of Multiple Myeloma Care? FDA Approves Tecvayli Combination Cure Today
Multiple Myeloma: Improved Prognosis With the Latest Treatments - Memorial Sloan Kettering Cancer Center
Multiple Myeloma: Improved Prognosis With the Latest Treatments Memorial Sloan Kettering Cancer Center
Myeloma Paper of the Day, April 7th, Suggested by Robert Orlowski - Oncodaily
Myeloma Paper of the Day, April 7th, Suggested by Robert Orlowski Oncodaily
Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM - CancerNetwork
Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM CancerNetwork
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study - Nature
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study Nature
Five Under 5: Top Oncology Videos for the Week of 3/29 - onclive.com
Five Under 5: Top Oncology Videos for the Week of 3/29 onclive.com
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly - Nature
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly Nature
Myelo 2026: Virtual Global Congress on Multiple Myeloma - Oncodaily
Myelo 2026: Virtual Global Congress on Multiple Myeloma Oncodaily
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target - Nature
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target Nature
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial - University of Miami
Antibody Therapy Eradicates Traces of Multiple Myeloma in Preliminary Trial University of Miami
“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma - Oncology News Central
“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma Oncology News Central
Inflammatory immune cells predict survival, relapse in multiple myeloma - WashU Medicine
Inflammatory immune cells predict survival, relapse in multiple myeloma WashU Medicine
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma - The University of Alabama at Birmingham
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma The University of Alabama at Birmingham
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease - Sanofi
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease Sanofi
CAR T Achieves 100% MRD Negativity in Newly Diagnosed Multiple Myeloma - Targeted Oncology
CAR T Achieves 100% MRD Negativity in Newly Diagnosed Multiple Myeloma Targeted Oncology
Distinguishing Strategic Roles of CELMoDs in Multiple Myeloma - Targeted Oncology
Distinguishing Strategic Roles of CELMoDs in Multiple Myeloma Targeted Oncology
Myeloma Paper of the Day, April 6th, Suggested by Robert Orlowski - Oncodaily
Myeloma Paper of the Day, April 6th, Suggested by Robert Orlowski Oncodaily
Diagnosis, risk stratification and management of smouldering multiple myeloma - Nature
Diagnosis, risk stratification and management of smouldering multiple myeloma Nature
"My company makes the medication that helped me fight multiple myeloma" - Johnson & Johnson
"My company makes the medication that helped me fight multiple myeloma" Johnson & Johnson
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts - Memorial Sloan Kettering Cancer Center
Diets for MGUS, Smoldering Myeloma, and Multiple Myeloma: Q&A With MSK Cancer and Nutrition Experts Memorial Sloan Kettering Cancer Center
Better Treatments Buoy Multiple-Myeloma Patients, Bound by Research Cuts and Racial Disparities - Journal of Health Economics and Outcomes Research
Better Treatments Buoy Multiple-Myeloma Patients, Bound by Research Cuts and Racial Disparities Journal of Health Economics and Outcomes Research
Are multiple myeloma rates higher in Western New York? - Roswell Park Comprehensive Cancer Center
Are multiple myeloma rates higher in Western New York? Roswell Park Comprehensive Cancer Center
Making Multiple Myeloma Treatment Choices: Teclistamab-Daratumumab (Tec-Dara) vs. CAR T-Cell Therapy - SurvivorNet
Making Multiple Myeloma Treatment Choices: Teclistamab-Daratumumab (Tec-Dara) vs. CAR T-Cell Therapy SurvivorNet
Established cancer drug gives multiple myeloma immunotherapy new lease of life - Oncology Central
Established cancer drug gives multiple myeloma immunotherapy new lease of life Oncology Central
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line - Johnson & Johnson
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line Johnson & Johnson
Researchers find men are more likely to develop multiple myeloma than are women - The University of Alabama at Birmingham
Researchers find men are more likely to develop multiple myeloma than are women The University of Alabama at Birmingham
Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance | Blood Cancer Journal - Nature
Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance | Blood Cancer Journal Nature
Bispecific Combo May Offer “Functional Cure” in Multiple Myeloma - Oncology News Central
Bispecific Combo May Offer “Functional Cure” in Multiple Myeloma Oncology News Central
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma - NEJM
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma NEJM